Yuancai Dong

Stabilized Amorphous State of Ibuprofen by Co-Spray Drying With Mesoporous SBA-15 to Enhance Dissolution Properties

A novel formulation process via co-spray drying ibuprofen (IBU) with mesoporous SBA-15 submicron particles exhibited excellence in production of stable amorphous IBU with significantly enhanced dissolution rate. With drug loading of IBU/SBA-15 ratio being 50:50 (w/w) or below, most drug molecules were entrapped inside the straight mesoporous channels via the co-spray drying and the morphology of SBA-15 submicron particles remained unchanged. IBU confined inside the mesoporous structure was in the amorphous state shown by PXRD and DSC measurements. The amorphous state of IBU in the solid dispersion showed remarkable stability when subject to stress test condition of 40 degrees C/75% RH in open pans for 12 months. The uniform pore walls were believed to prevent the re-crystallization of the homogeneously dispersed drug molecules inside the mesoporous channels with confined nanospace. The dissolution rate of IBU from the co-spray-dried solid dispersion was significantly enhanced to achieve a rapid release. Even after the accelerated stability test, the rapid drug release property was well preserved.

Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation

Due to low aqueous solubility and slow dissolution rate, spironolactone, a synthetic steroid diuretic, has a low and variable oral bioavailability. Nanoparticles were thus prepared by antisolvent precipitation in this work for accelerating dissolution of this kind of poorly water-soluble drugs. Effects of surfactant type/concentration and feed drug concentration on the precipitated particle size were evaluated. It was found that introduction of spironolactone solution in N-methyl-2-pyrrolidone (NMP) to the antisolvent water can produce the particles in the submicron range with hydroxypropyl methylcellulose (HPMC) as the stabilizer. The particle size decreased with the increase of HPMC concentration from 0 to 0.125% (w/v), further increase of which did not affect the size significantly. Increasing feed drug concentration from 10 to 100 mg/ml resulted in the particle size decrease. In comparison with raw drug, the chemical structure of nanosized spironolactone was not changed but the crystallinity was reduced. Dissolution of spironolactone nanoparticles in 0.1M HCl was 2.59 times faster than raw drugs in 60 min.

A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs

Rapid and homogeneous mixing of the solvent and antisolvent is critical to achieve submicron drug particles by antisolvent precipitation technique. This work aims to develop a continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs with spironolactone as a model drug. Continuous antisolvent production of drug nanoparticles was carried out with a SMV DN25 static mixer comprising 6-18 mixing elements. The total flow rate ranged from 1.0 to 3.0 L/min while the flow rate ratio of solvent to antisolvent was maintained at 1:9. It is found that only 6 mixing elements were sufficient to precipitate the particles in the submicron range. Increasing the number of elements would further reduce the precipitated particle size. Increasing flow rate from 1.0 to 3.0 L/min did not further reduce the particle size, while higher drug concentrations led to particle size increase. XRD and SEM results demonstrated that the freshly precipitated drug nanoparticles are in the amorphous state, which would, in presence of the mixture of solvent and antisolvent, change to crystalline form in short time. The lyophilized spironolactone nanoparticles with lactose as lyoprotectant possessed good redispersibility and showed 6.6 and 3.3 times faster dissolution rate than that of lyophilized raw drug formulation in 5 and 10 min, respectively. The developed static mixing process exhibits high potential for continuous and large-scale antisolvent precipitation of submicron drug particles.

Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers.

The purpose of this study is to synthesize chitosan (CS) nanoparticles (NPs) by ionic gelation with tripolyphosphate (TPP) as crossslinker in static mixers. The proposed static mixing technique showed good control over the ionic gelation process and 152-376 nm CS NPs were achieved in a continuous and scalable mode. Increasing the flow rates of CS:TPP solution streams, decreasing the CS concentration or reducing the CS:TPP solution volume ratio led to the smaller particles. Sylicylic acid (SA) was used as a model drug and successfully loaded into the CS NPs during the fabrication process. Our work demonstrates that ionic gelation-static mixing is a robust platform for continuous and large scale production of CS NPs for drug delivery.

DNA stretching in the nucleosome facilitates alkylation by an intercalating antitumour agent

DNA stretching in the nucleosome core can cause dramatic structural distortions, which may influence compaction and factor recognition in chromatin. We find that the base pair unstacking arising from stretching-induced extreme minor groove kinking near the nucleosome centre creates a hot spot for intercalation and alkylation by a novel anticancer compound. This may have far reaching implications for how chromatin structure can influence binding of intercalator species and indicates potential for the development of site selective DNA-binding agents that target unique conformational features of the nucleosome.

Solid lipid nanoparticles: Continuous and potential large-scale nanoprecipitation production in static mixers

This work aimed at developing continuous and scalable nanoprecipitation synthesis of solid lipid nanoparticles (SLN) by mixing lipids acetonic solution with water using static mixers. The developed platform exhibited good control over the nanoprecipitation process and enabled the production of SLN below 200 nm at a throughput of 37.5-150 g/h (for 25 mg/ml lipid solution at a flow rate of 25-100 ml/min). Among the several process parameters investigated, the lipid concentration played primary role in influencing the size of the SLN and higher lipid concentration resulted in relatively larger particles. Fenofibrate, a model drug, has been successfully loaded into the SLN. Our work demonstrates the potential of applying static mixing-nanoprecipitation for continuous and large scale production of SLN.

Clay as a matrix former for spray drying of drug nanosuspensions.

Utilization of sugars (e.g. lactose, sucrose) as matrix formers for spray drying of drug nanosuspensions is associated with two drawbacks: (1) sugars are incapable of preventing agglomeration of drug nanoparticles (NPs) in the suspension state; and (2) the spray-dried sugars are usually amorphous and hygroscopic. This work aimed to apply a clay, montmorillonite (MMT) as an alternative matrix former for spray drying of drug nanosuspensions with fenofibrate (feno) as a model compound. Drug nanosuspensions were synthesized by liquid antisolvent precipitation with different amount of MMT followed by spray drying. It is found that MMT is able to reduce the agglomeration of drug nanoparticles in the suspension state, as observed from the gradual alleviation of the clogging with the increased clay during the spray drying. The spray-dried feno NPs/MMT powders exhibited a much lower moisture sorption than spray-dried feno NPs/lactose powders as evidenced by the dynamic vapor sorption (DVS) analysis. The dissolution within 5 min for the spray-dried feno NPs/MMT powders at drug:MMT weight ratio of 1:3 was 81.4 ± 1.8% and the total dissolution within 60 min was 93.4 ± 0.9%. Our results demonstrate that MMT is a useful matrix former for preservation of the high dissolution rate of nanosized drug particles after drying.

Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation

Due to uniquely ordered nanoporous structure and high surface area as well as large pore volume, mesoporous materials have exhibited excellent performance in both controlled drug delivery with sustained release profiles and formulation of poorly aqueoussoluble drugs with enhanced bioavailability. Compared with other bulk excipients, mesoporous materials could achieve a higher loading of active ingredients and a tunable drug release profile, as the high surface density of surface hydroxyl groups offered versatility to be functionalized. With drug molecules stored in nano sized channels, the pore openings could be modified using functional polymers or nano-valves performing as stimuli-responsive release devices and the drug release could be triggered by environmental changes or other external effects. In particular, mesoporous silica nanoparticles (MSN) have attracted much attention for application in functional target drug delivery to the cancer cell. The smart nano-vehicles for drug delivery have showed obvious improvements in the therapeutic efficacy for tumor suppression as compared with conventional sustained release systems, although further progress is still needed for eventual clinical applications. Alternatively, unmodified mesoporous silica also exhibited feasible application for direct formulation of poorly water-soluble drugs to enhance dissolution rate, solubility and thus increase the bioavailability after administration. In summary, mesoporous materials offer great versatility that can be used both for on-demand oral and local drug delivery, and scientists are making great efforts to design and fabricate innovative drug delivery systems based on mesoporous drug carriers.

Solubilization and preformulation of poorly water soluble and hydrolysis susceptible N-epoxymethyl-1,8-naphthalimide (ENA) compound.

N-Epoxymethyl-1,8-naphthalimide (ENA) is a novel antiproliferative drug candidate with potent anticancer and antifungal activity. It has an aqueous solubility of 0.0116mg/mL and also exhibits hydrolytic instability with a first-order hydrolysis rate of 0.051 h(-1). The present preformulation study aimed to characterize the physicochemical properties of ENA and develop an early injectable solution formulation for preclinical studies. To minimize hydrolysis, ENA is proposed to be formulated as either lyophilized powders or nonaqueous solutions followed by solubilization/reconstitution prior to administration. ENA solubilization was investigated in both aqueous media (by cosolvency, micellization and complexation) and nonaqueous solutions (mixture of Cremophor EL and ethanol). It is found that none of the solubilization techniques in aqueous media could increase ENA solubility to a desired level of several hundreds microg/mL at pharmaceutically acceptable excipient concentrations (< or =10%). In contrast, a combination of 70% Cremophor EL and 30% ethanol (v/v) proved effective in solubilizing ENA at 4 mg/mL, which exhibited good physical and chemical stability on storage at both 4 degrees C and room temperature over 4 months. No precipitation was observed upon 5-20 times dilution by the saline; in addition, less than 5% of ENA was hydrolyzed in 4h for the saline-diluted aqueous solutions. This nonaqueous ENA formulation is thus proposed for further preclinical studies, which can be reconstituted, prior to administration, by the 5-20 times infusion fluids (saline, 5% dextrose, etc.) to the desired drug dosing concentration at the acceptable excipient level. The approach used in this work could serve as a useful reference in formulating nonpolar drugs with hydrolytic instability.

Nanostructured material formulated acrylic bone cements with enhanced drug release.

To improve antibiotic properties, poly(methyl methacrylate) (PMMA)-based bone cements are formulated with antibiotic and nanostructured materials, such as hydroxyapatite (HAP) nanorods, carbon nanotubes (CNT) and mesoporous silica nanoparticles (MSN) as drug carriers. For nonporous HAP nanorods, the release of gentamicin (GTMC) is not obviously improved when the content of HAP is below 10%; while the high content of HAP shows detrimental to mechanical properties although the release of GTMC can be substantially increased. As a comparison, low content of hollow nanostructured CNT and MSN can enhance drug delivery efficiency. The presence of 5.3% of CNT in formulation can facilitate the release of more than 75% of GTMC in 80 days, however, its mechanical strength is seriously impaired. Among nanostructured drug carriers, antibiotic/MSN formulation can effectively improve drug delivery and exhibit well preserved mechanical properties. The hollow nanostructured materials are believed to build up nano-networks for antibiotic to diffuse from the bone cement matrix to surface and achieve sustained drug release. Based on MSN drug carrier in formulated bone cement, a binary delivery system is also investigated to release GTMC together with other antibiotics.